Improving the Prognosis of Colon Cancer through Knowledge-Based Clinical-Molecular Integrated Analysis
Table 1
Detailed information of the data used for analysis.
Characteristic
Discovery set
Validation set
Reference set
TCGA-COAD
CPTAC
Normal samples
Patients,
374
98
41
Survival status, (%)
Alive
293 (78.3)
90 (91.8)
29 (70.7)
Dead
81 (21.7)
8 (8.2)
12 (29.3)
Agea in years, mean (SD, range)
66.75 (12.73, 31-90)
65.43 (11.56, 35-93)
70.34 (13.23, 40-90)
Gender, (%)
Male
199 (53.2)
41 (41.8)
20 (48.8)
Female
175 (46.8)
57 (58.2)
21 (51.2)
Overall survival time in months, mean (median, range)
30.24 (24.27, 0.47-150.07)
27.96 (30, 1-44)
27.66 (24.37, 0-101.40)
T stage, (%)
Not available
T1
9 (2.4)
0 (0)
T2
65 (17.4)
12 (12.2)
T3
258 (69.0)
73 (74.5)
T4
42 (11.2)
13 (13.3)
N stage, (%)
Not available
N0
226 (60.4)
52 (53.1)
N1
84 (22.5)
31 (31.6)
N2
64 (17.1)
15 (15.3)
M stage, n (%)
Not available
M0
315 (84.2)
91 (92.9)
M1
59 (15.8)
7 (7.1)
Number of genes,
10877
10877
10877
aThe characteristic “Age” refers to the age at initial diagnosis in the discovery set and reference set but refers to the age at procurement in the validation set. SD: standard deviation.
